Beta Bionics, Inc. (BBNX)
NASDAQ: BBNX · Real-Time Price · USD
8.85
-0.78 (-8.10%)
Apr 10, 2026, 2:49 PM EDT - Market open
Beta Bionics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Beta Bionics stock have a consensus rating of "Strong Buy" and an average price target of $24.78, which forecasts a 180.00% increase in the stock price over the next year. The lowest target is $14 and the highest is $40.
Price Target: $24.78 (+180.00%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Beta Bionics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 12 | 12 | 12 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $23 → $20 | Strong Buy | Maintains | $23 → $20 | +125.99% | Apr 9, 2026 |
| Stifel | Stifel | Strong Buy Maintains $25 → $22 | Strong Buy | Maintains | $25 → $22 | +148.59% | Feb 18, 2026 |
| Baird | Baird | Hold Maintains $28 → $14 | Hold | Maintains | $28 → $14 | +58.19% | Feb 18, 2026 |
| Stifel | Stifel | Strong Buy Maintains $31 → $25 | Strong Buy | Maintains | $31 → $25 | +182.49% | Feb 4, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $37 → $25 | Strong Buy | Maintains | $37 → $25 | +182.49% | Feb 2, 2026 |
Financial Forecast
Revenue This Year
135.24M
from 100.25M
Increased by 34.90%
Revenue Next Year
182.07M
from 135.24M
Increased by 34.63%
EPS This Year
-1.95
from -1.81
EPS Next Year
-1.96
from -1.95
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 141.5M | 203.7M | |||
| Avg | 135.2M | 182.1M | |||
| Low | 127.5M | 156.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 41.2% | 50.6% | |||
| Avg | 34.9% | 34.6% | |||
| Low | 27.2% | 15.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.55 | -1.19 | |||
| Avg | -1.95 | -1.96 | |||
| Low | -2.28 | -2.75 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.